PPD Development

• NCT06816433

  Collaborator, Phase 2, Suspended, 200 people, 10 Feb 2025

• NCT06093672

  Collaborator, Phase 3, Recruiting, 220 people, 23 Oct 2023

• NCT04969263

  Collaborator, Phase 2, Completed, 81 people, 20 Jul 2021

• NCT04903054

  Collaborator, Phase 2, Withdrawn, 0 people, 26 May 2021

• NCT04502966

  Collaborator, Phase 2, Completed, 199 people, 6 Aug 2020

• NCT04229979

  Collaborator, Phase 3, Active, not recruiting, 127 people, 18 Jan 2020

• NCT03654040

  Collaborator, Phase 1/2, Terminated, 42 people, 31 Aug 2018

• NCT03644667

  Collaborator, Phase 2, Completed, 385 people, 23 Aug 2018

• NCT03504241

  Collaborator, Phase 1, Completed, 8 people, 20 Apr 2018

• NCT02831673

  Collaborator, Phase 3, Completed, 719 people, 13 Jul 2016

• NCT02651428

  Collaborator, Phase 3, Completed, 806 people, 11 Jan 2016

• NCT02586155

  Collaborator, Phase 3, Completed, 2,425 people, 26 Oct 2015

• NCT02293837

  Collaborator, Phase 2, Completed, 136 people, 18 Nov 2014

• NCT02229240

  Collaborator, Phase 3, Withdrawn, 0 people, 1 Sept 2014

• NCT02229227

  Collaborator, Phase 3, Completed, 814 people, 1 Sept 2014

• NCT02097173

  Collaborator, Phase 1, Completed, 35 people, 26 Mar 2014

• NCT02081300

  Collaborator, Phase 3, Completed, 315 people, 7 Mar 2014

• Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient

  Collaborator, Phase 1, Completed, 105 people, 7 Jun 2013

• NCT01850004

  Collaborator, Phase 2, Completed, 84 people, 9 May 2013

• NCT01809301

  Collaborator, Phase 1, Completed, 20 people, 12 Mar 2013

Sources: clinicaltrials.gov